The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
ENESTnd 5-year (y) update: Long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib (IM).
Richard A. Larson
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Dong-Wook Kim
Consultant or Advisory Role - Bristol-Myers Squibb; Il-Yang ; Novartis; Pfizer
Honoraria - Bristol-Myers Squibb; Novartis
Research Funding - Bristol-Myers Squibb; Novartis
Saengsuree Jootar
No relevant relationships to disclose
Ricardo Pasquini
No relevant relationships to disclose
Richard E. Clark
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Clarisse Lobo
Honoraria - Novartis
Stuart L. Goldberg
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Hirohiko Shibayama
Honoraria - Novartis
Research Funding - Novartis
Andreas Hochhaus
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis
Giuseppe Saglio
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer
Hagop M. Kantarjian
No relevant relationships to disclose
Charisse Kemp
Employment or Leadership Position - Novartis
Weiping Deng
Employment or Leadership Position - Novartis
Hans D. Menssen
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Timothy P. Hughes
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis